Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis

Life Sciences
Rosanna SestitoAnna Bagnato

Abstract

In epithelial ovarian cancer (EOC), activation of endothelin-1 (ET-1)/endothelin A receptor (ETAR) and ET-1/ETBR signaling is linked to many tumor promoting effects, such as proliferation, angiogenesis, invasion, metastasis and chemoresistance. Understanding how to hamper the distinct mechanisms that facilitate epithelial plasticity and propagation is therefore central for improving the clinical outcome for EOC patients. The phosphorylation status of Akt and MAPK was evaluated by immunoblotting in A2780 and 2008 EOC cell lines and their cisplatinum-resistant variants. Vasculogenic mimicry was analyzed by vascular tubules formation assay. Tumor growth and metastases inhibition was performed in chemoresistant EOC xenografts. We found that the dual ETAR/ETBR antagonist macitentan was able to inhibit the ET-1-induced activation of Akt and MAPK signaling pathways in chemoresistant EOC cells. Moreover, chemoresistant EOC cells displayed higher capability to engage vasculogenic mimicry compared to sensitive cells that was inhibited after treatment with macitentan. Finally, the specific ETAR antagonist zibotentan was less efficacious compared to macitentan to suppress tumor growth in chemoresistant EOC xenografts and the co-treatment o...Continue Reading

References

Sep 17, 1999·The American Journal of Pathology·A J ManiotisM J Hendrix
Apr 6, 2001·The American Journal of Pathology·A K SoodM J Hendrix
Mar 6, 2009·Nature Reviews. Cancer·Kornelia Polyak, Robert A Weinberg
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lana E KandalaftGeorge Coukos
Jan 12, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura RosanòAnna Bagnato
Jun 18, 2011·Trends in Pharmacological Sciences·Sudha K Shenoy, Robert J Lefkowitz
Jan 13, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dawn A KirschmannMary J C Hendrix
Jun 2, 2012·The Journal of Biological Chemistry·Ralph FrancesconeRong Shao
Jan 12, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susana Banerjee, Stanley B Kaye
Jul 26, 2013·Nature Reviews. Cancer·Laura RosanòAnna Bagnato
Jun 25, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sun-Jin KimIsaiah J Fidler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis